In this area you will be able to:
- Propose, vote on, and discuss research ideas
- View current studies
- View published research
Here, you can submit a research idea to the community, cast your votes, and discuss research ideas proposed by other members. Please make your research question as specific as possible. Other members will vote on your research idea, and we will prioritize research ideas with the most votes.
You are allowed to vote for your own proposed research idea if you want. However, you can only vote for a total of five research ideas. If you have already cast your five votes and an idea you like even more is proposed, you can change your votes at any time to reflect your current preferences.
The research team will review all submitted ideas and provide a response to you and to the community. If your idea leads to an IBD Partners Study, you will have the opportunity to serve as a patient collaborator on the research team for that study.
We encourage you to prioritize the ideas that are most important to you, even if the research team determines that your idea is not a good fit for IBD Partners. We will share ideas labeled “Not a Good Fit” with researchers outside of our network when appropriate. We want to make sure all of your votes count!
Thanks for your participation in this important platform to help the IBD research community understand what research questions are important to patients. We are passionate about finding answers to your questions!
Does the human microbiome affect the development of mastocytic enterocolitis in patients with inflammatory bowel disease?
My gastroenterologist and primary care doctor both suggest that they are seeing an increased number patients with IBD and mast cell colitis. As mastocytic enterocolitis is a relatively new diagnosis, there doesn't seem to be much information about causation yet.
Are biosimilars equally effective maintaining remission in patients who achieved remission with the “brand” TNF-blocker?
I was at a recent CCF educational session and the gastroenterologist giving a talk said that VA patients, stable on infliximab, were switched to the biosiomilar, presumably for cost. Some did not do was well after the switch. If someone is stable on a TNF-blocker, what is the risk of their illness worsening if switched to the biosimilar?
How many IBD patients have ever been referred for counseling or offered an antidepressant by their gastroenterologist?
Depression and anxiety levels are very high in this population. Extending care to the whole person would make sense in managing disease and quality of life.
Patient Perception of Chronic Illness Care in a Large Inflammatory Bowel Disease Cohort
Immunization Rates and Vaccine Beliefs Among Patients with Inflammatory Bowel Disease: An Opportunity for Improvement